In a recent phase 1 clinical trial of the JAK inhibitor ruxolitinib with the anti-PD-1 antibody nivolumab, Zak et al. found that the combination of agents yielded the best overall response rate in patients with Hodgkin lymphoma who were refractory or relapsed after prior ICI therapy. Here, PDCD1 is linked to Hodgkins lymphoma.